Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12307
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFleet, Jamie Len
dc.contributor.authorWeir, Matthew Aen
dc.contributor.authorMcArthur, Ericen
dc.contributor.authorOzair, Sundusen
dc.contributor.authorDevereaux, Philip Jen
dc.contributor.authorRoberts, Matthew Aen
dc.contributor.authorJain, Arsh Ken
dc.contributor.authorGarg, Amit Xen
dc.date.accessioned2015-05-16T01:58:16Z
dc.date.available2015-05-16T01:58:16Z
dc.date.issued2014-07-16en
dc.identifier.citationAmerican Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation 2014; 64(6): 883-91en
dc.identifier.govdoc25037562en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12307en
dc.description.abstractAtenolol and metoprolol tartrate are commonly prescribed β-blockers. Atenolol elimination depends on kidney function, whereas metoprolol tartrate does not. We hypothesized that compared to metoprolol tartrate, initiating oral atenolol treatment would be associated with more adverse events in older adults, with the association most pronounced in patients with lower baseline estimated glomerular filtration rates (eGFRs).Population-based matched retrospective cohort study.Older adults (mean age, 75 years) in Ontario, Canada, prescribed oral atenolol versus metoprolol tartrate from April 2002 through December 2011. The 2 groups were well matched (n=75,257 in each group), with no difference in 31 measured baseline characteristics. Patients with end-stage renal disease were ineligible, and 4.6% of patients had chronic kidney disease (median eGFR, 38mL/min/1.73m(2) assessed through a database algorithm).β-Blocker type and eGFR.A composite outcome of hospitalization with bradycardia or hypotension and all-cause mortality were assessed in 90-day follow-up.Compared to metoprolol tartrate, initiating atenolol treatment was not associated with higher risk of hospitalization with bradycardia or hypotension (incidence, 0.71% vs 0.79%; relative risk, 0.90; 95%CI, 0.80-1.01). Atenolol treatment initiation was associated with lower 90-day risk of mortality than metoprolol tartrate (incidence, 0.97% vs 1.44%; relative risk, 0.68; 95%CI, 0.61-0.74). Lower eGFR did not modify either association (P for interaction=0.5 and 0.6, respectively).Heart rate and blood pressure were not available in our data sources, and effects ascertained from observational studies are subject to residual confounding.Contrary to our expectation, we found that atenolol versus metoprolol tartrate was associated with lower 90-day risk of mortality in patients regardless of eGFR, with no difference in risk of hospitalization with bradycardia or hypotension.en
dc.language.isoenen
dc.subject.otherAtenololen
dc.subject.otheradverse eventsen
dc.subject.otherbeta-blockeren
dc.subject.otherbradycardiaen
dc.subject.otherchronic kidney disease (CKD)en
dc.subject.otherdrug safetyen
dc.subject.otherelderlyen
dc.subject.otherhypotensionen
dc.subject.othermetoprolol tartrateen
dc.subject.otherolder adultsen
dc.subject.otherrenal functionen
dc.subject.otherAdministration, Oralen
dc.subject.otherAdrenergic beta-1 Receptor Antagonists.administration & dosageen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAtenolol.administration & dosageen
dc.subject.otherCohort Studiesen
dc.subject.otherFemaleen
dc.subject.otherFollow-Up Studiesen
dc.subject.otherHumansen
dc.subject.otherKidney.drug effects.physiologyen
dc.subject.otherMaleen
dc.subject.otherMetoprolol.administration & dosageen
dc.subject.otherPopulation Surveillance.methodsen
dc.subject.otherRenal Insufficiency, Chronic.drug therapy.epidemiology.physiopathologyen
dc.subject.otherRetrospective Studiesen
dc.subject.otherTreatment Outcomeen
dc.titleKidney function and population-based outcomes of initiating oral atenolol versus metoprolol tartrate in older adults.en
dc.typeJournal Articleen
dc.identifier.journaltitleAmerican journal of kidney diseases : the official journal of the National Kidney Foundationen
dc.identifier.affiliationDivision of Nephrology, Department of Medicine, Western University, London, Canada; Institute for Clinical Evaluative Sciences, Ontario, Canada; Department of Epidemiology & Biostatistics, Western University, London, Canadaen
dc.identifier.affiliationDepartment of Nephrology, Austin Health, Melbourne, Australiaen
dc.identifier.affiliationSchulich School of Medicine and Dentistry, Western University, London, Canadaen
dc.identifier.affiliationInstitute for Clinical Evaluative Sciences, Ontario, Canadaen
dc.identifier.affiliationDivision of Nephrology, Department of Medicine, Western University, London, Canadaen
dc.identifier.affiliationDivision of Nephrology, Department of Medicine, Western University, London, Canada; Institute for Clinical Evaluative Sciences, Ontario, Canadaen
dc.identifier.affiliationDivision of Cardiology, Department of Medicine, McMaster University, Hamilton, Canadaen
dc.identifier.doi10.1053/j.ajkd.2014.06.009en
dc.description.pages883-91en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25037562en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Apr 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.